8 withdrawn. 8 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Withdrawn 8 |
| Phase 2 | 2 | Withdrawn 2 |
Follow Neurodevelopmental Disorders: new trials by email Literature Review of Neurodevelopmental Disorders trials Research Report on Neurodevelopmental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness of a Digital Strategy-based Educational Skills Group for Secondary Students With Organization and Academic Motivation Challenges BPT/OST, Peer Support - ADHD | Phase 2 / Phase 3 | Withdrawn | Seattle Children's Hospital | 2022-05-18 | 2026-04-24 | |
| Efficacy and Safety of Slenyto for Insomnia in Children With ASD Melatonin, Placebo - Autism Spectrum Disorder | Phase 3 | Withdrawn | Neurim Pharmaceuticals Ltd. | 2020-09-01 | 2021-03-12 | |
| Classroom Study of SPN-812 in Children With ADHD Placebo, 200 mg SPN-812 - ADHD | Phase 3 | Withdrawn | Supernus Pharmaceuticals, Inc. | 2019-08-01 | 2019-09-18 | |
| Melatonin in Youth: N-of-1 Trials in a Stimulant-treated Attention Deficit Hyperactivity Disorder (ADHD) Population Melatonin, Placebo - Attention Deficit/Hyperactivity Disorder, Initial Insomnia | Phase 3 | Withdrawn | University of Alberta | 2019-01-01 | 2021-11-15 | |
| Cortical Metrics in Intervention Trials With Autism Spectrum Disorders Dextromethophan - Autism Spectrum Disorders | Phase 2 / Phase 3 | Withdrawn | Duke University | 2015-08-01 | 2016-08-25 | |
| Event Rate and Effects of Stimulants in ADHD LDX., sugar pill, computer task (Go/No-Go task) - Attention Deficit Hyperactivity Disorder | Phase 3 | Withdrawn | University Ghent | 2014-01-01 | 2021-12-02 | |
| Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) SPD489, Placebo - ADHD | Phase 3 | Withdrawn | Shire | 2011-03-06 | 2021-06-03 | |
| A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators SPD465, Placebo - Attention Deficit Hyperactivity Disorder | Phase 3 | Withdrawn | Shire | 2007-04-30 | 2021-07-06 |
Attention Deficit Disorder with Hyperactivity (6) · Autism Spectrum Disorder (2) · Autistic Disorder (1)
Mental Disorders (8) · Attention Deficit and Disruptive Behavior Disorders (6) · Child Development Disorders, Pervasive (2)
Melatonin (2) · Electroencephalography (1) · Lisdexamfetamine Dimesylate (1) · Sugars (1)
Shire (2) · Duke University (1) · Neurim Pharmaceuticals Ltd. (1) · Seattle Children's Hospital (1) · Supernus Pharmaceuticals, Inc. (1) · University Ghent (1) · University of Alberta (1)
United States (3) · Belgium (1) · Canada (1)
Edmund Sonuga-Barke, PhD (1) · Herbert Roeyers, PhD (1) · Linmarie Sikich, MD (1) · Rudy van Coster, MD, PhD (1) · Stefan Schwabe, MD (1) · Sunita Vohra, MD (1)